Paul Patton, PA
Surgical · Fairbanks, AKNPI 1437401502
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.1%), travel and lodging and education — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Teleflex LLC at 54.8% of the total. Reporting peaked in 2024 at $1,448 and has fallen 91.3% since, to $127 in 2025.
Across 42 payments — averaging $53.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$1K
- Astellas Pharma US Inc$275
- AbbVie$194
- Endo USA, Inc.$77
- Accord Healthcare, Inc.$62
- 180 Medical, Inc.$57
- plus $353 from 13 others
What the payments were for
- Travel & lodging$91140%
- Food & beverage$1,24355%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 3 | $1,235 |
| Astellas Pharma US Inc | 10 | $275 |
| AbbVie | 5 | $194 |
| Endo USA, Inc. | 3 | $77 |
| Accord Healthcare, Inc. | 1 | $62 |
| 180 Medical, Inc. | 2 | $57 |
| AstraZeneca | 3 | $49 |
| Bayer | 2 | $47 |
| Novo Nordisk | 2 | $41 |
| Antares Pharma, Inc. | 2 | $40 |
| Olympus America Inc. | 1 | $32 |
| Ambu Inc. | 1 | $24 |
| Novartis | 1 | $22 |
| Urogen Pharma, Inc. | 1 | $19 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
| Shield Therapeutics Inc | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Halozyme Inc | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,254 in reported general payments places this provider in the 80th percentile of 31 surgical providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 25 | $32,672 |
| TrulicityDulaglutide | 24 | $31,968 |
| MyrbetriqMirabegron | 16 | $13,507 |
| GemtesaVibegron | 19 | $13,113 |
| Testosterone Cypionate | 37 | $3,010 |
| Testosterone | 18 | $2,917 |
| Tamsulosin Hcl | 138 | $2,364 |
| Rosuvastatin Calcium | 83 | $1,977 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 28 | $1,066 |
| Finasteride | 41 | $851 |
| Lisinopril | 100 | $823 |
| Metoprolol Succinate | 44 | $578 |
| Levothyroxine Sodium | 43 | $447 |
| Amlodipine Besylate | 71 | $411 |
| Omeprazole | 40 | $392 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $14 | $31,96824 claims |
| Astellas Pharma US IncMyrbetriq | $275 | $13,50716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 31 surgical providers in Alaska.
Other surgical in Fairbanks
- Jennifer HoltFairbanks$2K
- Lydia KnuthsFairbanks$2K
- Jennifer LuceyFairbanks$394
- Angela BrittFairbanks$159
- Candace HickelAnchorage$12K
- Susan HartmannAnchorage$5K
- Cheukyin PangAnchorage$3K
- Jayme FullerAnchorage$3K
- Kristina EllisAnchorage$2K
- Haley WagonerSoldotna$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.